Ironwood Pharmaceuticals, Inc.
| Nasdaq: IRWD
Ironwood Pharmaceuticals, Inc. is an entrepreneurial pharmaceutical company. It discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. The company's lead product candidate is linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation. It operates Human Therapeutics segment, which consists of the development and commercialization of product candidates, including linaclotide. The company also focuses on both research and development of early stage product candidates and preclinical research in multiple therapeutic areas, including gastrointestinal disease, pain and inflammation, respiratory disease, allergic disease and cardiovascular disease. Ironwood Pharmaceuticals was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.